Persistent symptoms and decreased health-related quality of life after symptomatic pediatric COVID-19: A prospective study in a Latin American tertiary hospital

Carregando...
Imagem de Miniatura
Citações na Scopus
30
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Citação
CLINICS, v.76, article ID e3511, 7p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVES: To prospectively evaluate demographic, anthropometric and health-related quality of life (HRQoL) in pediatric patients with laboratory-confirmed coronavirus disease 2019 (COVID-19) METHODS: This was a longitudinal observational study of surviving pediatric post-COVID-19 patients (n=53) and pediatric subjects without laboratory-confirmed COVID-19 included as controls (n=52) was performed. RESULTS: The median duration between COVID-19 diagnosis (n=53) and follow-up was 4.4 months (0.8-10.7). Twenty-three of 53 (43%) patients reported at least one persistent symptom at the longitudinal follow-up visit and 12/53 (23%) had long COVID-19, with at least one symptom lasting for >12 weeks. The most frequently reported symptoms at the longitudinal follow-up visit were headache (19%), severe recurrent headache (9%), tiredness (9%), dyspnea (8%), and concentration difficulty (4%). At the longitudinal follow-up visit, the frequencies of anemia (11% versus 0%, p=0.030), lymphopenia (42% versus 18%, p=0.020), C-reactive protein level of >30 mg/L (35% versus 0%, p=0.0001), and D-dimer level of >1000 ng/mL (43% versus 6%, p=0.0004) significantly reduced compared with baseline values. Chest X-ray abnormalities (11% versus 2%, p=0.178) and cardiac alterations on echocardiogram (33% versus 22%, p=0.462) were similar at both visits. Comparison of characteristic data between patients with COVID-19 at the longitudinal follow-up visit and controls showed similar age (p=0.962), proportion of male sex (p=0.907), ethnicity (p=0.566), family minimum monthly wage (p=0.664), body mass index (p=0.601), and pediatric pre-existing chronic conditions (p=1.000). The Pediatric Quality of Live Inventory 4.0 scores, median physical score (69 [0-100] versus 81 [34-100], p=0.012), and school score (60 [15-100] versus 70 [15-95], p=0.028) were significantly lower in pediatric patients with COVID-19 at the longitudinal follow-up visit than in controls. CONCLUSIONS: Pediatric patients with COVID-19 showed a longitudinal impact on HRQoL parameters, particularly in physical/school domains, reinforcing the need for a prospective multidisciplinary approach for these patients. These data highlight the importance of closer monitoring of children and adolescents by the clinical team after COVID-19.
Palavras-chave
Long Coronavirus Disease 2019, Child, Adolescent, Sequelae, Multisystem Inflammatory Syndrome in Children
Referências
  1. Alveno RA, 2018, J PEDIAT-BRAZIL, V94, P539, DOI 10.1016/j.jped.2017.07.014
  2. Ashkenazi-Hofthung L, 2021, PEDIATR INFECT DIS J, V40, pE509, DOI 10.1097/INF.0000000000003285
  3. Astley C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.705250
  4. Pereira MFB, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e2209
  5. Beavis KG, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104468
  6. Bozzini AB, 2019, J PEDIAT-BRAZIL, V95, P87, DOI 10.1016/j.jped.2017.10.013
  7. Passone CGB, 2020, REV PAUL PEDIATR, V38, DOI 10.1590/1984-0462/2020/38/2018101
  8. Buonsenso D, 2021, ACTA PAEDIATR, V110, P2208, DOI 10.1111/apa.15870
  9. Busatto GF, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-051706
  10. Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
  11. Denina M, 2020, PEDIATR INFECT DIS J, V39, pE458, DOI 10.1097/INF.0000000000002937
  12. Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
  13. Farooqi KM, 2021, PEDIATRICS, V148, DOI 10.1542/peds.2021-051155
  14. Ferreira JC, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e2294
  15. Huang LX, 2021, LANCET, V398, P747, DOI 10.1016/S0140-6736(21)01755-4
  16. Klatchoian DA, 2008, J PEDIAT-BRAZIL, V84, P308, DOI [10.2223/JPED.1788, 10.1590/S0021-75572008000400005]
  17. Lavorato SSM, 2021, CLINICS, V76, DOI 10.6061/clinics/2021/e2688
  18. Ludvigsson JF, 2021, ACTA PAEDIATR, V110, P914, DOI 10.1111/apa.15673
  19. Maia MM, 2016, SEMIN ARTHRITIS RHEU, V46, P338, DOI 10.1016/j.semarthrit.2016.07.002
  20. Marques IG, 2021, CLINICS, V76, DOI 10.6061/clinics/2021/e2655
  21. Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z
  22. Neder L, 2015, REV BRAS REUMATOL, V55, P414, DOI [10.1016/j.rbr.2014.12.013, 10.1016/j.rbr.2015.01.003]
  23. Safadi MAP, 2021, REV PAUL PEDIATR, V39, DOI 10.1590/1984-0462/2020/38/2020192
  24. Palmeira P, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1947
  25. Penner J, 2021, LANCET CHILD ADOLESC, V5, P473, DOI 10.1016/S2352-4642(21)00138-3
  26. Pinto AJ, 2020, NAT REV RHEUMATOL, V16, P347, DOI 10.1038/s41584-020-0427-z
  27. Radtke T, 2021, JAMA-J AM MED ASSOC, V326, P869, DOI 10.1001/jama.2021.11880
  28. Ramos GF, 2019, J PEDIAT-BRAZIL, V95, P667, DOI 10.1016/j.jped.2018.06.006
  29. Diniz MDR, 2021, ARQ BRAS CARDIOL, V117, P954, DOI 10.36660/abc.20200920
  30. Say D, 2021, LANCET CHILD ADOLESC, V5, pE22, DOI 10.1016/S2352-4642(21)00124-3
  31. Shen B, 2020, AM J TRANSL RES, V12, P1348
  32. Silva CA, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1931
  33. Singh S, 2020, PSYCHIAT RES, V293, DOI 10.1016/j.psychres.2020.113429
  34. Sousa BLA, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e2273
  35. Yasuhara J, 2020, PEDIATR PULM, V55, P2565, DOI 10.1002/ppul.24991
  36. de Paula CSY, 2021, J INFECTION, V83, pE22, DOI 10.1016/j.jinf.2021.04.030